YMAB — Y-mAbs Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $643.96m
- $565.32m
- $84.82m
- 50
- 17
- 79
- 47
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 20.8 | 34.9 | 65.3 | 84.8 |
Cost of Revenue | |||||
Gross Profit | — | — | 32.6 | 57.8 | 73.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 83 | 141 | 150 | 160 | 110 |
Operating Profit | -83 | -120 | -115 | -94.8 | -25.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -81 | -119 | -55.3 | -95.6 | -20.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -81 | -119 | -55.3 | -95.6 | -21.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -81 | -119 | -55.3 | -95.6 | -21.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -81 | -119 | -55.3 | -95.6 | -21.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.3 | -2.97 | -2.72 | -2.19 | -0.424 |